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Abstract 49 
Background 50 
Pathology has evolved from a purely morphological description of cellular alterations in 51 
disease to our current ability to interrogate tissues with multiple ‘omics’ technologies. By 52 
utilising these techniques and others, ‘molecular diagnostics’ acts as the cornerstone of 53 
precision/personalised medicine by attempting to match underlying disease mechanisms to 54 
the most appropriate targeted therapy. 55 
Methods 56 
Despite the promises of molecular diagnostics, significant barriers have impeded its 57 
widespread clinical adoption. Thus, the National Cancer Research Institute (NCRI) Cellular 58 
Molecular Pathology (CM-Path) initiative convened a national Molecular Diagnostics Forum 59 
to facilitate closer collaboration between clinicians, academia, industry, regulators and 60 
other key stakeholders in an attempt to overcome these. 61 
Results 62 
We agreed a consensus ‘roadmap’ that should be followed during development and 63 
implementation of new molecular diagnostic tests. We identified key barriers to efficient 64 
implementation and propose possible solutions to these. In addition, we discuss the recent 65 
reconfiguration of molecular diagnostic services in NHS England and its likely impacts. 66 
Conclusions 67 
We anticipate that this consensus statement will provide practical advice to those involved 68 
in the development of novel molecular diagnostic tests. Although primarily focusing on test 69 
adoption within the United Kingdom, we also refer to international guidelines to maximise 70 
the applicability of our recommendations.  71 
 72 
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Background 73 
Pathology – the study of disease – has evolved significantly since its beginnings with 74 
Virchow and a purely morphological description of cellular alterations, to our current ability 75 
to make fine resolution observations at the subcellular/molecular scale.1 We can now use 76 
this knowledge and modern molecular biological techniques to interrogate human tissue 77 
samples in increasingly sophisticated ways, with the ultimate aim of providing more 78 
accurate diagnoses that can better guide treatment choices. In the field of cellular 79 
pathology, it is now possible to supplement traditional light microscopic assessment of 80 
tissue samples with a vast array of information at genomic, epigenomic, transcriptomic, 81 
proteomic and metabolomic levels. Thus, molecular diagnostics is now the cornerstone of 82 
precision/personalised medicine, in which individual patients receive customised healthcare 83 
on the basis of their specific test results, and has the potential to revolutionise patient care 84 
and improve outcomes, as exemplified by its use in haematological malignancies.2 The 85 
application of molecular diagnostics is currently being expanded into other clinical areas; for 86 
example, in the United Kingdom (UK), the 100 000 Genomes Project has brought whole 87 
genome sequencing into routine clinical practice by initially applying this technique to 88 
cancer and rare diseases.3 89 
 90 
Despite the promises of molecular diagnostics, significant barriers have impeded its 91 
widespread clinical adoption.4 Until recently, there has been a lack of national strategy for 92 
molecular diagnostic testing with complex commissioning and funding arrangements.5 93 
Moreover, the National Health Service (NHS) is currently poorly equipped to embrace fully 94 
this healthcare revolution. In particular, the substantial attrition of academic pathology in 95 
the UK over the past two decades, coupled with the increasing service demands placed on 96 
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pathologists, means that many diagnostic laboratories lack the knowledge, expertise and 97 
capacity to introduce these new tests efficiently.6 Additionally, the interaction between 98 
clinicians, academia, industry and regulators required to expedite the development of new 99 
molecular diagnostic tests and their introduction into clinical practice has not been 100 
uniformly present to date.  101 
 102 
Inception of a cross-sector molecular diagnostics forum 103 
In 2016, the National Cancer Research Institute (NCRI) launched its Cellular Molecular 104 
Pathology (CM-Path) initiative with the aim of supporting modernisation of pathology in the 105 
UK and, in so doing, help to develop the workforce and infrastructure required to provide 106 
nationwide molecular diagnostic services (https://cmpath.ncri.org.uk). To advance 107 
pathology in the UK, and thus ensure that patients receive the highest quality of care 108 
possible, CM-Path recognises the value of collaborating with industry, regulators and other 109 
key stakeholders. To this end, members of CM-Path workstream 4 (‘Technology and 110 
Informatics’) convened the first meeting of the CM-Path Molecular Diagnostics Forum on 111 
26th January 2018 at the Royal Society of Medicine in London. The overarching aims of the 112 
forum are:  113 
• To define infrastructure, regulatory and workflow requirements for the adoption of 114 
molecular diagnostics in NHS pathology laboratories; 115 
• To develop protocols to ensure faster and more efficient implementation of 116 
emerging technologies and novel bespoke and validated molecular panels; 117 
• To assist in the education/training of the workforce required to provide high quality, 118 
nationwide molecular diagnostic services; 119 
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• To actively engage pathologists with industry and regulators to develop the next 120 
phase of molecular diagnostic tests; 121 
• To form links with companies developing software to assist in test interpretation and 122 
correlation between molecular findings and clinical outcomes. 123 
 124 
Ultimately, we wish to ensure that all patients across the UK have equitable and rapid 125 
access to effective molecular diagnostic tests, whether developed by industry or academia. 126 
The objectives of this particular meeting, which was attended by 25 individuals including 127 
clinicians, academics and representatives from industry and regulatory bodies, were to 128 
define a ‘roadmap’ for molecular diagnostic test development and NHS implementation and 129 
to identify the challenges (and their possible solutions) that are likely to be encountered 130 
during these processes. The meeting commenced with invited case presentations on the 131 
development and implementation of new molecular diagnostic tests in rare ophthalmic 132 
disease (Professor Graeme Black, University of Manchester) and bladder cancer (Dr Andrew 133 
Feber, University College London), providing illuminating ‘real world’ insights into these 134 
processes. Summaries of the perspectives of industry and of the National Institute for 135 
Health and Care Excellence (NICE) on the current state of affairs were also presented by 136 
Jane Coppard (Public Affairs Manager at Roche) and Rebecca Albrow (Senior Technical 137 
Adviser in the NICE Diagnostics Assessment Programme), respectively. It was highlighted 138 
that NICE diagnostics guidance recommendations are typically made by the Diagnostic 139 
Advisory Committees (DAC), an independent decision-making body that bases its 140 
recommendations on review of clinical and economic evidence. Once recommendations are 141 
made, NICE diagnostics guidance is published on the NICE website 7 and is disseminated to 142 
all stakeholders, which include professional societies, patient organisations and individual 143 
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clinicians. NICE also creates tools to support the adoption of guidance but there are many 144 
factors that can hinder nationwide uptake. Until recently, there has been no systematic 145 
method of tracking the use of diagnostics within the NHS and, therefore, the impact of NICE 146 
recommendations cannot be directly evaluated. 147 
 148 
Developing a roadmap for the development and implementation of new molecular 149 
diagnostic tests 150 
In a subsequent breakout session, delegates were grouped by professional background and 151 
tasked to create a roadmap describing the stages in the development of a new molecular 152 
diagnostic test, from initial concept to clinical implementation. This is particularly important 153 
as, compared to therapeutics, the validation and approval processes for diagnostic tests are 154 
poorly defined. It quickly became clear that no single group was able to map the entire 155 
pathway, immediately justifying the value of arranging this multidisciplinary meeting. 156 
Ultimately, a final roadmap was agreed by consensus between the groups (Figure); access to 157 
carefully curated tissues specimens through biobanks, health economics and workforce 158 
education are key aspects that have central relevance to the entire process. The discussions 159 
were very much centred on test development in the UK, although many companies 160 
developing such products are multinational or would aim to market internationally. 161 
Although not the focus of the workshop, it was also acknowledged that new diagnostic tests 162 
are often introduced alongside new therapies (as ‘companion diagnostics’), so the 163 
development of novel molecular diagnostic tests often occurs in parallel to drug 164 
development. In this instance, the clinical need would be very clear and specific at the 165 
outset but otherwise the overall roadmap would still be similar. 166 
 167 
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FIGURE 168 
 169 
Challenges to the implementation of new molecular diagnostic tests 170 
The groups were then mixed and asked to identify challenges that are likely to be 171 
encountered within the roadmap. Several key themes emerged during this discussion; 172 
importantly, a number of innovative solutions were also suggested (Table).  173 
 174 
TABLE 175 
 176 
A follow-up meeting was held in October 2018 to discuss these challenges in greater detail, 177 
and to consider how our roadmap will likely be impacted by the reconfiguration of genomic 178 
laboratory services within NHS England that took place that month.8 By creating a single 179 
national testing network co-ordinated through seven Genomic Laboratory Hubs (GLHs), this 180 
reconfiguration aims to expedite widespread adoption of molecular diagnostics into routine 181 
clinical practice and to ensure that such tests are conducted to uniform standards, thus 182 
providing consistent and equitable care across the country. Building upon the success of the 183 
100 000 Genomes Project, this project forms part of the Government’s Life Sciences 184 
Strategy,9 and aims to develop a world leading Genomic Medicine Service within the NHS, as 185 
well as to support scientific research and innovation more broadly. The new service now 186 
includes a National Genomic Test Directory for both cancer and rare and inherited 187 
diseases.10 This directory specifies which tests are available within the NHS and how they 188 
are funded, which patients are eligible to receive these tests and which technology 189 
platforms should be used to perform each test. The directory will be updated annually, 190 
based on recommendation from a Clinical and Scientific Expert Panel that will evaluate new 191 
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genomic tests and determine which existing tests should be retired or replaced. The authors 192 
believe that this positive development will help with many of the challenges that we have 193 
identified but, crucially, it only currently covers genetic testing and not other forms of 194 
molecular diagnostics (e.g. infectious disease). 195 
 196 
Whilst this new system should help to deliver more uniform nationwide access to molecular 197 
diagnostic tests, some scope for local flexibility in testing strategy is likely to be of benefit to 198 
patient care. A crucial issue to consider when ordering a molecular diagnostic test is how 199 
this test is best integrated into each patient’s individual care pathway and we envisage that 200 
local multidisciplinary team (MDT) meetings will continue to play an important role in 201 
making such decisions. Some test results are needed more urgently than others and this can 202 
influence the type of test selected and whether this is performed locally or sent externally. 203 
For example, one-step nucleic acid amplification (OSNA) testing to detect cytokeratin19 204 
(CK19) mRNA copy numbers in homogenised axillary lymph node samples, as a marker of 205 
breast cancer sentinel lymph node metastasis, has been performed in some UK centres for 206 
many years, with rapid intra-operative results determining the requirement for nodal 207 
clearance as part of a one-step procedure.11 Likewise, lung cancer mutation status can have 208 
a significant impact upon immediate clinical management and rapid in-house testing can be 209 
very useful, particularly in the context of acutely unwell patients or where a prompt initial 210 
screening test result can avoid the need to perform further unnecessary tests (for example, 211 
KRAS mutations are generally mutually exclusive with EGFR and ALK mutations in lung 212 
cancer, which therefore do not need to be tested for when a KRAS mutation is detected).12 213 
Initially, MDTs may also wish to arrange local funding for specific tests, rather than incur the 214 
time penalty involved in sending samples away. Nevertheless, the majority of molecular 215 
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diagnostic tests are not urgent (for example, screening for Lynch syndrome in colorectal 216 
cancer)13 and are therefore likely to be best performed in a centralised reference 217 
laboratory. Furthermore, over time, we hope that the GLHs will generate evidence to 218 
demonstrate that centralised testing can return results in a clinically relevant timeframe for 219 
most indications. Another reason to retain local testing might be when a centre has already 220 
developed expertise in the performance and interpretation of a specific test, which could 221 
not be delivered to the same standard through an associated GLH.  222 
 223 
It was felt by forum participants that GLHs could play an important part in the development 224 
of novel molecular tests by providing access to high quality human tissue samples via linked 225 
academic biobanks and by assisting in test validation, particularly by facilitating rigorous 226 
comparison with established tests and by recruiting patients into clinical trials. Once an 227 
evidence base has been established, a key milestone for any new molecular test will be 228 
inclusion in the test directory and it is envisaged that this step could be aligned with 229 
approval by the NICE DAC. GLHs will also have responsibility for implementing newly 230 
approved tests, ideally working in collaboration with each other to ensure optimal quality 231 
control, and in monitoring test uptake and downstream clinical effects, for example by 232 
transmitting relevant information derived from genomic MDT meetings to a centralised 233 
repository of outcome data. Likely future challenges for the GLHs include extending 234 
molecular tests to include other ‘omics’ approaches (e.g. epigenomics, transcriptomics, 235 
proteomics and metabolomics) whilst at the same time ensuring standardised, high-quality 236 
performance of established techniques (e.g. PD-L1 immunohistochemistry in non-small cell 237 
lung cancer, for which several different assays are available).14 This may also entail the 238 
incorporation of digital pathology, which is currently being promoted via an Innovate UK 239 
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initiative with the establishment of five centres of excellence for digital pathology, image 240 
analysis and Artificial Intelligence.15 Such approaches are likely to become part of integrated 241 
reporting, bringing together the clinical, morphological, immunohistochemical and 242 
molecular data, in order to improve diagnostics and patient management. 243 
 244 
Centralised testing offers many benefits but there are also potential downsides to such an 245 
approach and lessons should be learnt from previous reconfigurations of pathology 246 
services.16 Whilst earlier consolidations have produced cost savings,17 a large initial financial 247 
investment is often required, for example to cover the cost of new transport networks and 248 
to develop the Information Technology (IT) infrastructure required to connect different 249 
hospitals/laboratories. Critically, the NHS workforce remains central to the provision of 250 
high-quality diagnostic testing and there is a risk of loss of valuable expertise amongst staff 251 
who are not based in GLHs. Furthermore, sending tissue samples away for testing may 252 
negatively impact upon the ability of ‘non-hub’ centres to contribute to biobanking activities 253 
that are critical to support biomedical research. Given these risks, and to foster a new 254 
molecular medicine culture within the NHS, it is imperative that the seven GLHs (and their 255 
associated ‘spoke’ hospitals) adopt a collaborative, rather than competitive, approach to 256 
service delivery. Importantly, shared leadership by pathology, genetic and clinical services 257 
will be needed to deliver a truly integrated service. 258 
 259 
Nationwide delivery of a ‘cutting-edge’ molecular diagnostics service will require large scale 260 
upskilling of the current laboratory workforce, as well as amendments to the training of 261 
medical students, junior doctors and clinical scientists. With this requirement in mind, CM-262 
Path, in collaboration with other relevant organisations, is actively working to develop 263 
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training opportunities in molecular pathology.18, 19 Importantly, a requirement for formal 264 
molecular pathology teaching is now included in the Royal College of Pathologists (RCPath) 265 
‘Curriculum for Specialty Training in Histopathology’;20 a two-week molecular pathology 266 
attachment for Histopathology trainees is now advocated 21 and trainee knowledge of this 267 
area will be evaluated both through workplace-based assessment and formal professional 268 
examinations. The curriculum is currently undergoing further revision and it is envisaged 269 
that molecular pathology will feature even more prominently in the next iteration. In 270 
parallel, Health Education England (HEE), in partnership with several leading UK universities, 271 
provides formal postgraduate qualifications in Genomic Medicine as part of its Genomics 272 
Education Programme, as well as numerous other online learning resources 273 
(https://www.genomicseducation.hee.nhs.uk). Additionally, a range of professional training 274 
courses in molecular pathology are also available: ‘Molecular Pathology and Diagnosis of 275 
Cancer’ delivered by the Wellcome Genome Campus and RCPath,22 ‘UK Molecular 276 
Diagnostics Training School’ delivered by the Nottingham Molecular Pathology Node,23 277 
‘Molecular Pathology Study Day’ organised by the British Division of the International 278 
Academy of Pathology (BDIAP) 24 and ‘Getting to Grips with Genomics’ which is a joint 279 
initiative between CM-Path, RCPath and HEE and, importantly, provides education in 280 
molecular pathology to both trainees and trainers alike.25 281 
 282 
Finally, legal, accreditation and regulatory frameworks must be considered when selecting 283 
or developing new molecular diagnostic tests. New in vitro diagnostic devices (IVD) must be 284 
approved before clinical adoption; regulatory guidelines for such approval exist both within 285 
the UK 26 and the European Union (EU).27 In the UK, the Medicines and Healthcare products 286 
Regulatory Agency (MHRA) is responsible for ensuring that medical devices are safe for 287 
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clinical use. Currently, there is a Europe-wide transition to the new EU Regulation on In Vitro 288 
Diagnostic Medical Devices 2017/746.28 This regulation sets out a new pathway for 289 
certification that will be carried out by approved Notified Bodies and Conformité 290 
Européenne In Vitro Diagnostic (CE IVD) approval is a sign of conformity with European 291 
standards. Whilst still to be confirmed, it is likely that these changes will apply in the UK 292 
even after its withdrawal from the EU.  In the UK, all molecular assays and laboratory 293 
processes must also be accredited by the United Kingdom Accreditation Service (UKAS) 294 
through meeting a range of different International Organization for Standardization (ISO) 295 
requirements. UKAS also require that IVDs undergo External Quality Assessment (EQA), with 296 
such quality control exercises most commonly conducted by the United Kingdom National 297 
External Quality Assessment Service (UK NEQAS). In the United States of America, IVDs are 298 
classified based on likely patient risk and are usually required to undergo Premarket 299 
Approval (PMA), unless there is a specific exemption.29 Through the Molecular Diagnostics 300 
Forum, for example, CM-Path is working closely with the MHRA and The British In Vitro 301 
Diagnostic Association (BIVDA) in order to ensure that regulators are involved at an early 302 
stage in the development of new diagnostic tests. 303 
 304 
Conclusions and future perspectives 305 
Our NCRI CM-Path Molecular Diagnostics Forum meetings proved to be highly constructive 306 
in identifying strengths and weaknesses in the application of molecular pathology across the 307 
NHS and the group is committed to facilitate continued collaboration between pathology (in 308 
both the NHS and academia), industry and regulators. To our knowledge, this is the first 309 
cross-sector attempt at defining the roadmap for molecular diagnostic tests, from 310 
conception through to deployment and use in accredited laboratories within the NHS. 311 
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Whilst this process is currently complex, we believe that many of the challenges that we 312 
have identified can be overcome through closer collaboration between key stakeholders 313 
and with the network of GLHs. The next forum meeting will have a specific emphasis on 314 
addressing optimal sample handling for molecular testing, how the new ‘hub and spoke’ 315 
arrangement of GLHs will impact upon specimen journey from patient to laboratory and 316 
how molecular testing at GLHs can be potentially integrated with digital pathology being 317 
performed at the above-mentioned five new centres. Lessons learned will be integrated into 318 
the roadmap, further developing molecular diagnostics capabilities in the UK. 319 
 320 
CM-Path would be delighted to hear from any individual or group who feels that the 321 
Molecular Diagnostics Forum is relevant to their work and who would like to attend future 322 
meetings – please email cmpath@ncri.org.uk to get in touch. 323 
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Figure legends 525 
Figure – Consensus ‘roadmap’ for the development and implementation of molecular 526 
diagnostic tests (Key: CD = companion diagnostic, IP = Intellectual Property). 527 
1. Identify need – researchers define a clinical scenario which would benefit from 528 
improved diagnostic capabilities or there is a specific need for a companion diagnostic 529 
test in parallel to drug development;  530 
2. Early discovery and proof of concept – pre-clinical studies to develop scientific basis of 531 
new discovery (we acknowledge that in some cases this may precede the previous step 532 
with clinical relevance only emerging after the initial scientific discovery); 533 
3. Testing and validation – further testing, possibly in preparation for human trials 534 
(discussed in greater detail by Mattocks and colleagues);31 535 
4. Formal consultation on regulatory approval and Intellectual Property – we recommend 536 
discussions with the relevant regulatory bodies and technology transfer offices at an 537 
early stage in test development (for example, the United Kingdom Accreditation Service 538 
[UKAS – https://www.ukas.com] and the Medicines and Healthcare products Regulatory 539 
Agency (MHRA)’s Innovation Office),30 to ensure that the correct procedures are being 540 
followed and that Intellectual Property is protected (N.B. must also consider the need 541 
for Research and Ethics Committee [REC] and Human Tissue Authority [HTA] approval, 542 
which are required for testing on human tissue samples); 543 
5. Identification of position in patient care pathway – before clinical trials are conducted, it 544 
is essential to identify where a new test will fit within the current or redesigned patient 545 
care pathway, not just within the United Kingdom but also other countries, especially 546 
Europe and the United States of America; 547 
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6. Clinical trial (conducted according to ethical and regulatory framework) and clinical 548 
outcome data – a formal clinical trial demonstrating equivalence/superiority to the 549 
current ‘gold standard’ diagnostic test may be required; 550 
7. Regulatory approval – evidence from proof of concept studies and clinical trials will be 551 
required to gain relevant regulatory approval (Conformité Européenne marking of In 552 
Vitro Diagnostics [CE IVD] in Europe by Notified Bodies and the Food and Drug 553 
Administration [FDA] in the United Stated of America); 554 
8. Commercialisation and commissioning – after regulatory approval has been granted, the 555 
new diagnostic test requires marketing and must be deemed to provide clinical benefit 556 
and be cost-effective (i.e. by the National Institute for Health and Care Excellence 557 
[NICE]) before it will be commissioned for clinical use within the NHS; 558 
9. Implementation – the new test is implemented in clinical practice; 559 
10. Quality control – rigorous quality control and post-marketing surveillance is required to 560 
ensure ongoing, high quality test performance (for example, in the UK, laboratory 561 
accreditation is regulated by UKAS and external assessment is conducted by 562 
International Organization for Standardization (ISO) 17043 accredited external quality 563 
assurance providers [listed at http://www.eptis.org];32 in the specialty of 564 
histopathology, this is most commonly undertaken by the United Kingdom National 565 
External Quality Assessment Service [UK NEQAS – https://ukneqas.org.uk]); 566 
11. Monitor uptake and outcomes – important to monitor nationwide uptake of new 567 
molecular diagnostic tests and to provide firm evidence that the tests provide clinical 568 
and/or economic benefit; 569 
12. Review technology – ongoing review of the technology, identifying areas for further 570 
development/optimisation is essential. 571 

 
Table – Challenges to the development and implementation of new molecular 
diagnostic tests and possible solutions to these 
Challenge Solutions 
1. NHS commissioning and standardisation of testing 
-Limited pathology budgets and current 
funding structures mean that tests that 
could improve patient outcomes (and even 
save money in the long-term) may not be 
funded 
 
-Many different tests available (including 
for the same biomarker), leading to 
regional variation in testing 
 
 
- The timing of investigations within 
diagnostic/management pathways can 
influence choice of testing method 
 
 
 
-When a new therapy has been 
recommended by NICE, the NHS should 
commission funding for the companion 
diagnostic test, but this hasn’t always been 
the case 
 
-Innovative tests that may have a disruptive 
effect on local NHS pathways may be less 
likely to be adopted 
 
-Variation in how tissue samples are 
collected and processed and in how tests 
are performed and interpreted 
-Lobbying for alternative funding sources 
and changes to how tariffs are allocated 
 
 
 
 
-Rigorous assessment of different tests, 
leading to greater understanding of their 
strengths and weaknesses, with the aim of 
uniform adoption of the optimal test 
 
-Within reason, flexibility should be 
encouraged in the new national testing 
system to ensure that patients have access 
to the most appropriate test at each point 
in their care pathway 
 
-Ensure NICE and the NHS are aligned so 
that when a new therapy is recommended 
by NICE there is timely uptake of any 
companion diagnostic test 
 
 
-Centralised commissioning of testing (as 
with the recent reconfiguration of genomic 
testing within the NHS) 
 
-Development of SOPs and regular 
participation in EQA schemes 
2. Ethical and regulatory issues 
-Requirement for ethical approval and 
consenting procedures during test 
development/clinical trials 
 
 
 
 
 
 
-Uncertainty about necessary regulatory 
requirements (e.g. clinical trial 
-Greater clarity with regard to when ethical 
approval and consent are and are not 
required (e.g. test development/validation 
vs. performance assessment of an already 
validated test) 
-Encourage researchers to seek ethical 
approval at an early stage in test 
development 
 
-Encourage researchers, clinicians and NHS 
managers to interact with regulators at an 
authorisation, EU IVDR, US FDA approval) 
for new molecular diagnostic tests and 
accreditation of laboratories performing 
them (uncertainty greater within academia 
and NHS than within industry) 
 
-Uncertainty about how ‘Brexit’ will affect 
regulation of in vitro diagnostics in the UK 
(the IVDR, an EU regulation, came in to 
effect in May 2017 and gave manufacturers 
five years to prepare for new legislation 
that will require more rigorous assessment 
of in vitro diagnostic medical devices – it is 
currently unknown how ‘Brexit’ will affect 
this) 
early stage in test development and 
implementation (e.g. through scientific 
advice, MHRA’s innovation office)30 
-Promotion of both UK26 and European27 
regulatory guidelines 
 
-Lobbying for clarification of 
legislative/regulatory impact of ‘Brexit’ and 
possible exemptions from new EU 
regulations, when appropriate 
3. Information technology  
-Development of standardised, robust IT 
infrastructures 
 
 
-Data storage and sharing 
 
 
 
 
-Volume and complexity of data 
 
-Investment in IT infrastructure, ensuring 
new software are compatible with existing 
ones  
 
-Consideration of technical, legal and 
ethical issues to ensure that data can be 
safely stored and shared for clinical and 
research purposes 
 
-Development of novel computational 
approaches (e.g. AI) to facilitate automated 
analyses 
4. NHS culture 
-Staff must be aware of emerging 
technologies and willing to adopt them 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Patients should be educated and 
empowered to ensure they receive 
appropriate molecular testing 
-Improved nationwide dissemination of 
information about established/emerging 
tests and funding sources 
-Greater communication between 
specialties (such as at the MDT meeting), to 
encourage reflex testing by pathologists, 
when appropriate 
-RCPath to include NICE recommendations 
in their best practice guidelines and 
datasets 
-Sharing of case studies demonstrating 
clinical benefit and cost-effectiveness 
-A national workshop involving clinical staff, 
laboratory scientists and NHS managers 
 
-Education and mentoring of patients and 
enhanced communication between 
patients, clinicians and pathologists (e.g. 
 through the NCRI Consumer Forum) 
5. Education/training 
-Urgent need to upskill NHS workforce in 
molecular diagnostics 
-Inclusion of molecular diagnostics in UG 
medical curricula and increased 
prominence in PG training, including 
training of senior staff 
(CM-Path is actively working to develop 
training opportunities in molecular 
pathology)18, 19 
-Cross-discipline and cross-sector training 
to include clinicians, pathologists, nurses, 
managers and industry 
-Identify best practice examples in 
molecular diagnostics training from other 
countries 
6. Monitoring of uptake/response  
-Lack of systematic monitoring of molecular 
diagnostic testing in the NHS, leading to a 
knowledge gap regarding current practices 
across the UK 
 
 
 
-Lack of data regarding clinical impact of 
test adoption 
-NHS genomic reconfiguration to introduce 
a new molecular diagnostics test directory 
and commissioning system 
-Inclusion of molecular diagnostics in 
quarterly NHS England Innovation 
Scorecard produced by HSCIC 
 
-Mandatory recording of how new tests 
have influenced patient care (e.g. 
treatment allocation) 
Key: AI – Artificial Intelligence; EQA – external quality assessment; EU – European Union; 
HSCIC – Health and Social Care Information Centre; IT – information technology; IVDR – In 
Vitro Diagnostic Regulation; MDT – multidisciplinary team; MHRA – Medicines and 
Healthcare products Regulatory Agency; NICE – National Institute for Health and Care 
Excellence; NCRI – National Cancer Research Institute; NHS – National Health Service; PG – 
postgraduate; RCPath – The Royal College of Pathologists; SOPs – standard operating 
procedures; UG – undergraduate; UK – United Kingdom; USFDA – United States Food and 
Drug Administration 
